DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Abstract
Although platinum compounds are the first-line treatment for ovarian cancer, the majority of patients relapse and develop resistance to treatment. However, the mechanism underlying resistance is unclear. The goal of our study is to decipher the mechanism by which a metabolic kinase, diacylglycerol kinase alpha (DGKA), confers platinum resistance in ovarian cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3790
Entities
People
- Anna D. Umano
- Austin C. Boese
- Chaoyun Pan
- Jie Li
- Jihoon Kang
- Kelly R. Magliocca
- Lingtao Jin
- Sagar Lonial
- Sumin Kang
- Wenqing Yang
- Yu Zhang
Organizations
- American Cancer Society
- Central South University
- Emory University
- Emory University School of Medicine
- National Institutes of Health
- United States Department of Defense
- University of Florida
- Winship Cancer Institute